Immunic reveals $42.3 million Q3 net loss
Key points
- Immunic (NASDAQ:IMUX) reported a third-quarter 2026 net loss of approximately $42.3 million, or $0.99 per share, compared with a $25.6 million loss a year earlier.
- Research and development expenses increased to $23.9 million from $20 million, while general and administrative expenses rose to $19.4 million from $6 million.
- The company expects December 2026 results from its fully enrolled Phase 3 ENSURE trials, with a potential U.S. regulatory submission in mid-2027 if results are positive.
Immunic (NASDAQ:IMUX) reported a third-quarter 2026 net loss of approximately $42.3 million, or $0.99 per basic and diluted share, as it continued developing treatments for multiple sclerosis.
The loss widened from approximately $25.6 million a year earlier, although loss per share narrowed from $1.32 as the weighted-average number of outstanding shares increased.
Research and development expenses increased to $23.9 million from $20 million, while general and administrative expenses rose to $19.4 million from $6 million.
The company's fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium are expected to produce topline results in December 2026, with positive findings potentially supporting a U.S. regulatory application targeted for mid-2027.
Cash and cash equivalents totaled $132 million at September 30, 2026, and Immunic expects its available funding to support operations into late 2027.
The company also plans to begin enrolling patients in its Phase 3 ProTEct-MS trial for progressive multiple sclerosis in the first half of 2027, while targeting potential U.S. approval of vidofludimus calcium in 2028 if the ENSURE results support an application.
